Please login to the form below

Not currently logged in

Delay for inhaled hypertension treatment

United Therapeutics has announced it is likely to face regulatory delays for the inhaled version of its hypertension drug Remodulin

United Therapeutics Corp today announced it is likely to face regulatory delays for the inhaled version of its hypertension drug Remodulin because of Food and Drug Administration (FDA) concerns over patient instructions.

The company had expected a decision from the FDA by April 30, but will likely face delays because of questions over instructions for using the nebuliser that delivers the drug.

United Therapeutics is a biotechnology company focused on the development and commercialisation of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. The company already sells the drug as an injection called Remodulin. The inhaled version is called Tyvaso.

"Following our most recent discussion with the FDA, we have agreed to conduct human factors testing to validate that the revised instructions for use (IFU) results in the proper use of the device by a naive user," said President and Chief Operating Officer Roger Jeffs, in a statement. "This relatively small study in normal subjects will test the new IFU in its ability to guide patients to accomplish such tasks as proper device assembly, drug administration, disassembly and cleaning, among other things."

Shares of United Therapeutics sank $2 (or 3 per cent) to $66.28 in pre-market activity.

16th March 2009


Featured jobs

Subscribe to our email news alerts


Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...